As per Fortune Business Insights, the preimplantation genetic testing market size was valued at USD 928.78 billion in 2025 and is projected to grow from USD 995.65 billion in 2026 to USD 1,736.79 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 7.2% during the forecast period.
The global Preimplantation Genetic Testing Market is experiencing substantial expansion, driven by rising maternal age, increasing utilization of assisted reproductive technologies, and growing clinical demand for high-accuracy embryo screening.
Market Overview
The preimplantation genetic testing sector encompasses specialized laboratory assays, next-generation sequencing platforms, and biopsy workflows utilized during in vitro fertilization to screen embryos for chromosomal abnormalities, monogenic disorders, and structural rearrangements. Supported by specialized fertility clinics and advanced genomic laboratories, these procedures maximize implantation success rates and reduce the risk of miscarriage.
Market Insights
Industry insights highlight an accelerated adoption of next-generation sequencing and artificial intelligence-assisted embryo assessment tools, enabling laboratories to detect mosaicism with superior sensitivity. Furthermore, strategic partnerships between fertility clinics and diagnostics firms continue to streamline genetic testing workflows and expand regional accessibility.
Market Trends
- Rapid integration of artificial intelligence and machine learning platforms to enhance automated embryo selection and clinical triage.
- Surging deployment of advanced next-generation sequencing kits offering higher throughput and reduced turnaround times for genetic screening.
- Expanding carrier screening panels identifying at-risk couples prior to in vitro fertilization cycles.
- Strategic acquisitions and collaborations among leading diagnostics laboratories to broaden specialized genomic testing menus.
For detailed market insights, visit the Preimplantation Genetic Testing Market reports: https://www.fortunebusinessinsights.com/preimplantation-genetic-testing-market-111730
Market Growth Factors
- Rising global utilization of assisted reproductive technologies and an increasing trend toward delayed childbearing and advanced maternal age.
- Growing awareness and diagnosis of monogenic and inherited genetic conditions among prospective parents.
- Continuous technological breakthroughs in high-throughput sequencing accuracy, sample amplification, and embryo biopsy safety.
- Expanding insurance reimbursement policies and public healthcare support in select regions reducing out-of-pocket costs.
For request sample reports: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/preimplantation-genetic-testing-market-111730
Competitor Analysis
The competitive landscape of the market features prominent genomics laboratories, biotechnology enterprises, and specialized fertility diagnostics providers focusing heavily on technological innovation, workflow automation, and strategic partnerships. Key industry participants invest significantly in high-throughput sequencing research, proprietary bioinformatics software, and global clinical validation to secure competitive advantages and maintain strong market positioning.
Segmentation Analysis
The market is comprehensively segmented by test type, application, embryo source, technology, and geography. By test type, it covers preimplantation genetic testing for aneuploidy (PGT-a, holding the dominant market share), preimplantation genetic testing for monogenic disorders (PGT-m), and preimplantation genetic testing for structural rearrangements (PGT-sr). Based on application and embryo source, the segmentation includes fresh and frozen non-donor and donor cycles across specialized fertility centers and genetic laboratories.
Regional Insights
Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global preimplantation genetic testing market with a revenue share of 38% in 2025, supported by advanced fertility infrastructure, high disposable incomes, and early adoption of novel genomic screening technologies in the United States. Meanwhile, Europe and Asia Pacific exhibit robust growth rates propelled by expanding IVF clinic networks and increasing reproductive health awareness.
Explore Japan’s Market Opportunities - Latest Preimplantation Genetic Testing Market Insights